mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy

T Tian, X Li, J Zhang - International journal of molecular sciences, 2019 - mdpi.com
The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …

[HTML][HTML] L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia

Q Wang, J Holst - American journal of cancer research, 2015 - ncbi.nlm.nih.gov
The L-type amino acid transporter (LAT) family are Na+-independent transporters, which
deliver neutral amino acids into cells. The four LATs, LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 …

Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors

SZ Millis, S Ikeda, S Reddy, Z Gatalica… - JAMA oncology, 2016 - jamanetwork.com
Importance Molecular aberrations in the phosphatidylinositol-3-kinase (PI3K) pathway drive
tumorigenesis. Frequently co-occurring alterations in hormone receptors and/or human …

Prostate cancer, PI3K, PTEN and prognosis

HM Wise, MA Hermida, NR Leslie - Clinical science, 2017 - portlandpress.com
Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

MP Edlind, AC Hsieh - Asian journal of andrology, 2014 - journals.lww.com
Prostate cancer (PCa) is the second most common malignancy among men in the world.
Castration-resistant prostate cancer (CRPC) is the lethal form of the disease, which …

Therapeutic targeting of cancers with loss of PTEN function

LM Dillon, TW Miller - Current drug targets, 2014 - ingentaconnect.com
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is one of the most
frequently disrupted tumor suppressors in cancer. The lipid phosphatase activity of PTEN …

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

HJ Lim, P Crowe, JL Yang - Journal of cancer research and clinical …, 2015 - Springer
Purpose PTEN is an essential tumour suppressor gene which encodes a phosphatase
protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this …

[HTML][HTML] Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities

P Toren, A Zoubeidi - International journal of oncology, 2014 - spandidos-publications.com
Abstract The PI3K/Akt pathway is an actively pursued therapeutic target in oncology. In
prostate cancer, the activation of this pathway appears to be characteristic of many …

Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications

C Pisano, M Tucci, RF Di Stefano, F Turco… - Critical reviews in …, 2021 - Elsevier
In last years several improvements have been made in the management of prostate cancer
(PCa). Androgen receptor (AR) is considered the main driver in PCa growth and progression …

Inhibitors of the PI3K/Akt/mTOR pathway in prostate cancer chemoprevention and intervention

NM Roudsari, NA Lashgari, S Momtaz, S Abaft… - Pharmaceutics, 2021 - mdpi.com
The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of
the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the …